There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kala Pharmaceuticals Inc (NASDAQ:KALA), Akebia Therapeutics (NASDAQ:AKBA) and Anavex Life Sciences (NASDAQ:AVXL) with bullish sentiments.
Kala Pharmaceuticals Inc (KALA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kala Pharmaceuticals Inc, with a price target of $35. The company’s shares closed yesterday at $12.84, close to its 52-week low of $11.81.
Selvaraju noted:
“Our 12-month price target is derived from a market value of the firm at $1.0B, which includes a discounted cash flow-based asset value of $1.1B for INVELTYS (85% probability of success) and KPI-121 0.25% (65% probability of success), with a 15% discount rate and 0.5% terminal growth rate.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -1.7% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals Inc with a $33.67 average price target, a 162.2% upside from current levels. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $47 price target.
.
See today’s analyst top recommended stocks >>
Akebia Therapeutics (AKBA)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Akebia Therapeutics, with a price target of $22. The company’s shares closed yesterday at $8.22, close to its 52-week low of $7.77.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.9% and a 42.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Paratek Pharmaceuticals.
Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $19.60, which is a 138.4% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $21 price target.
.
Anavex Life Sciences (AVXL)
H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Anavex Life Sciences today and set a price target of $10. The company’s shares closed yesterday at $2.83.
According to TipRanks.com, Kolbert is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.0% and a 38.7% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Can-Fite BioPharma, and Keryx Biopharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anavex Life Sciences with a $8.50 average price target, representing a 200.4% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $7 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVXL:
